Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of mirtazapine on depression and insomnia in Parkinson’s disease
KCT0010033Phase 4Recruiting
- Sponsor
- The Korean Movement Disorder Society
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of mirtazapine in Parkinson's disease (PD), major depressive disorder (MDD), Insomnia, sponsored by The Korean Movement Disorder Society. Started Apr 2025; status: recruiting.
02
Drugs
mirtazapine
03
Conditions
Parkinson's disease (PD)major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on KCT0010033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010033.